Before medicines and new treatment methods become available to the public, they undergo clinical trials, which is part of the ...

These biotech IPOs plan to move forward during shutdown © 2025 American City Business Journals. All rights reserved. Use of ...

Neurologists at Florida Atlantic University have launched a new research tool combining focused ultrasound and magnetic ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Reducing cholesterol levels might not just be good for your heart; they might also be effective at reducing your risk of ...

The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Texans live with dementia. If voters approve Prop 14, patients will get access to early intervention treatments, more ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the ...

Potomac-based IGC Pharma Inc. has been selected as a semifinalist in the prestigious $1 million Alzheimer's Insights AI Prize ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...